Neurological Biomarkers Market Size, Share and Trends 2025 to 2034

Neurological Biomarkers Market Size and Forecast 2025 to 2034

The global neurological biomarkers market size was calculated at USD 9.14 billion in 2024 and is projected to surpass around USD 30.77 billion by 2034, expanding at a CAGR of 12.90% from 2025 to 2034. The benefits of neurological biomarkers include being used to track brain health by researchers measuring molecules, being helpful in more effective treatments, faster drug development, earlier diagnosis, and being less invasive, which helps the growth of the market.

Neurological Biomarkers Market Key Takeaways

• In terms of revenue, the market is valued at $10.32 billion in 2025.
• It is projected to reach $30.77 billion by 2034.
• The market is expected to grow at a CAGR of 12.90% from 2025 to 2034.
• North America dominated the neurological biomarkers market with the largest market share of 40% in 2024.
• Asia Pacific is estimated to be the fastest-growing during the forecast period of 2025-2034.
• By type, the proteomic biomarkers segment dominated the market in 2024.
• By type, the other segments are anticipated to grow significantly during the forecast period.
• By application, the Alzheimer’s disease segment dominated the market in 2024.
• By application, the Parkinson’s disease segment is expected to grow substantially during the forecast period.
• By end-use, the research organizations & others segment dominated the neurological biomarkers market in 2024.
• By end-use, the hospital & hospital laboratories segment is estimated to be the fastest-growing during the forecast period.

How can AI help the Neurological Biomarkers Industry?

Artificial intelligence (AI) can help to analyze wide data volumes, and biomarkers clinicians may miss and improve treatment and diagnosis accuracy. Machine learning (ML) algorithms can process high-data sets and patient information, developing accurate models for treatment and diagnosis. Current tools use AI for accurate brain mapping, surgical planning, and epilepsy diagnosis. The use of AI can improve diagnosis and treatment accuracy, explore biomarkers clinicians may miss, and analyze large data volumes. These factors help to the growth of the neurological biomarkers market.

• In September 2023, a $12.5 million AI startup was launched by Teenagers to monitor brain health.
• In July 2024, the fully automated Lumipulse G GFAP assay for research use only and to strengthen their neuro test menu was launched by H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio.

U.S. Neurological Biomarkers Market Size and Growth 2025 to 2034

The U.S. neurological biomarkers market size was exhibited at USD 2.74 billion in 2024 and is projected to be worth around USD 9.41 billion by 2034, growing at a healthy CAGR of 13.09% from 2025 to 2034.

North America dominated the neurological biomarkers market in 2024. In drug development, a rising understanding of the remarkable potential of biomarkers and the presence of regulatory bodies helps the growth of the market in North America. For the development of neurological biomarkers, government funding increased, which helped the growth of the market.

In Canada, one in 400 Canadian people, or more than 90000 people across Canada, live with MS (multiple sclerosis), a chronic, neurodegenerative disease that affects the central nervous system.

Canada is exceptional in the North American neurological biomarkers market because of its strong health care system, sophisticated research environment, and supportive government initiatives for neuroscience research.In Canada, one in 400 Canadian people, or more than 90000 people across Canada, live with MS (multiple sclerosis), a chronic, neurodegenerative disease that affects the central nervous system. Canada continues to invest in the development of biomarker-based diagnostics and monitoring of neurodegenerative diseases through institutions such as the University of Toronto and McGill University which are leading the way in its development. Canada has strong collaborations between health authorities, biotechnology companies and academia that further strengthen its lead in this area.

India ranks first place in the neurological biomarkers market in Asia due to its rapidly expanding healthcare industry, growing awareness and prevalence of neurological disorders, and investment in diagnostic technologies. With a large patient population and rising research into neurodegenerative diseases, there are opportunities to capitalize on the breadth of public and private sector investments and affordably priced diagnostic solutions combined with clinical trial activities to position India as an emerging leader in the growth of neurological biomarker applications in the region.

• In March 2024, approval of the ETNA-MS (Eye-Tracking Neurological Assessment for Multiple Sclerosis) was granted by Health Canada. It is for use in tracking disease progression in people living with multiple sclerosis (MS).

Asia Pacific is estimated to be the fastest-growing during the forecast period of 2024-2033. The rising senior population which is highly susceptible to these neurological diseases and the increasing prevalence of neurological diseases contribute to the growth of the market. India and China are the leading countries for the growth of the neurological biomarkers market in the Asia Pacific region.

• In July 2024, in Varanasi, India, a new ‘lab on chip’ biomarker or device to make easy and early detection of neurological conditions with unprecedented diseases was launched by the researchers at IIT-BHU (Indian Institute of Technology-BHU). It is helpful for more reliable and quicker detection of neurological diseases like Schizophrenia, Parkinson’s Disease, and depression.

Market Overview

The neurological biomarkers market is a dynamic and rapidly evolving sector in the broader field of life sciences and healthcare. Neurological biomarkers are key tools that allow the monitoring, diagnosis, and research of conditions affecting the central and peripheral nervous systems and neurological disorders. In neurodegenerative diseases, the identification of biomarkers is a major topic. Biomarkers are objectively evaluable and measurable indicators that serve to describe pathological processes, normal biological processes, and pharmacological responses to therapeutic intervention. The main aim of the use of biomarkers is to enhance clinical diagnosis in the sense of raising the accuracy of different diagnoses. These factors help to the growth of the market.

Neurological Biomarkers Market Growth Factors

• The benefits of neurological biomarkers include that they are used between few and far, which helps the growth of the neurological biomarkers market.
• Better technology is making it easier for researchers to track brain health by measuring molecules, which contributes to the market's growth.
• It includes, hopefully, more effective treatments, faster drug development, earlier diagnosis, and less invasive testing, which contribute to the market's growth.
• Neurological biomarkers' applications include autism spectrum disorder, multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease, which help to grow the market for them.

Market Scope

Market Dynamics

Drivers

Rising prevalence of neurological conditions

The rising prevalence of neurological conditions contributes to the growth of the market. Neurological conditions or disorders that affect the functions of the nervous system. This involves the peripheral nervous system and central nervous system. The causes of neurological conditions include stroke, tumors, injury or damage, abnormal development, infections, genetic disorders, aging, and exposure to pollutants. These disorders may cause behavioral, emotional, cognitive, and physical symptoms like coordination difficulties, mood changes, confusion, and pain. These factors help to the growth of the neurological biomarkers market.

Restraint

Challenges of neurological biomarkers

The challenges of neurological biomarkers include disadvantages such as laboratory errors, ethical responsibilities, normal range difficulty to start, longevity of sample or storage, expensive or high cost of analyses, and timing critical. These factors can hamper the growth of the market. Neurological biomarkers are crucial tools for understanding and diagnosing neurological disorders, but there are some disadvantages, including clinical challenges, technical issues, high cost and complexity, poor clinical diagnosis, lack of standardization, and limited accessibility. These factors can restrict the growth of the neurological biomarkers market.

Opportunity

Biomarker Research

The future opportunities of neurological biomarkers are encouraging and expected to significantly impact the management, diagnosis, and treatment of neurological disorders. There is an opportunity for advancement in biomarker research to understand the pathophysiology of neurological disorders and design therapeutic targets for effective mediation. To overcome challenges like laboratory errors, ethical responsibilities, normal range difficulty to start, longevity of samples, high cost of analyses, and critical timing by research and development in neurological biomarkers. These factors help the growth of the neurological biomarkers market.

Type Insights

The proteomic biomarkers segment dominated the neurological biomarkers market in 2024. In the field of medical research and diagnostics, proteomic biomarkers play an important role. The advantages of proteomic biomarkers include the detection of diseases like different types of cancer, understanding of disease pathogenesis, and the discovery of non-invasive diagnostic biomarkers that may be detected in biological samples like urine or blood, which help to make the diagnostic process less irritating for patients. In personalized treatments, proteomic biomarkers can indicate how a patient’s disease progresses and how they respond to specific treatments. Identification of proteomic biomarkers leads to the discovery of novel therapeutic targets, which lead to the development of more effective treatments.

The advantages also include the prediction of treatment side effects and monitoring treatment response, which will help the growth of the market. These factors help to the growth of the proteomic biomarkers segment and contribute to the growth of the market.

The other segment is anticipated to grow significantly during the forecast period. The other types include digital biomarkers, which help the growth of the market. The benefits of digital biomarkers include helping to allow for better health management, reducing the cost of clinical data collection, and providing personalized remote patient care. The capacity of wearable and mobile application technology to continually assess health data from many sources enables patients to better understand their disorders and to make better health decisions. It helps doctors to deliver remotely individualized care without the need to visit a hospital or a doctor. These factors help to grow the other types of digital biomarkers and contribute to the growth of the neurological biomarkers market.

• In April 2024, a licensing agreement with Braingaze Ltd and the initiation of Tris Digital Health was announced by Tris Pharma Inc. Tris Digital Health will help to develop and distribute digital diagnostics and therapeutic products for the treatment of neurological health disorders, ADHD (attention deficit/hyperactive disorder).

Application Insights

The Alzheimer’s disease segment dominated the neurological biomarkers market in 2024. In the treatment of Alzheimer’s disease, neurological biomarkers play an important role. Clinical diagnosis is based on the clinical phenotype; increasingly, biomarkers are available to differentiate between the different diseases and different Alzheimer’s disease phenotypes, mainly at the early stages, and help in identifying those at risk for symptomatic Alzheimer’s disease. Biomarkers of Alzheimer's disease help in the identification and treatment of neuropsychiatric symptoms of dementia, disease-modifying therapies, monitoring the impact of lifestyle intervention, aiding in differential diagnosis of mild cognitive impairment (MCI) and dementia, screening at-risk populations for disease, and aiding in planning for end-of-life care. These factors help the growth of the Alzheimer’s disease segment and contribute to the growth of the market.

• In January 2024, Cognito Therapeutics deepened its analysis to secure an FDA greenlight for its sound- and light-based neuromodulation device for treating Alzheimer's disease and launched a biomarker sub-study.
• In February 2024, aiming to develop Alzheimer’s disease risk biomarkers, the European Public-Private Predictom Initiative was launched.

The Parkinson’s disease segment is expected to grow substantially during the forecast period. Parkinson’s biomarkers are helpful for researchers in diagnosing earlier Parkinson’s disease with greater precision. It also helps to track disease progression and respond to the treatment. These factors help the growth of the Parkinson’s disease segment and contribute to the growth of the neurological biomarkers market.

End-use Insights

The research organizations & others segment dominated the neurological biomarkers market in 2024. In research organizations & others, biomarkers are uncommonly used in neurological disorders, but better technology is making it easier for researchers by measuring molecules to track brain health. This will hopefully lead to more effective treatments, faster drug development, earlier diagnosis, and less invasive testing. These factors help to the growth of the research organizations & other segments and contribute to the growth of the market.

The hospital & hospital laboratories segment is estimated to be the fastest-growing during the forecast period. In hospital & hospital laboratories, neurological biomarkers play an important role. Neuroimaging biomarkers are obtained from devices like DTI, MRI, and PET, which offer objective measures of mind shape and functions. In hospital & hospital laboratories, personalized medicinal drugs use neurological biomarkers to adopt remedies for individual patients based on their different needs and treatments. Neurological biomarkers can monitor progression and response to therapy, evaluate disease stage, and guide clinical diagnosis. These factors help the growth of the hospital & hospital laboratories segment and contribute to the growth of the neurological biomarkers market.

Neurological Biomarkers Market Companies

• Rules-Based Medicin
• Alseres Pharmaceuticals, Inc.
• Quanterix
• Banyan Biomarkers, Inc.
• DiaGenic ASA
• Johnson & Johnson Services, Inc.
• Bio-Rad Laboratories, Inc.
• Merck & Co., Inc
• Thermo Fischer Scientific, Inc.
• Abbott
• Olink Biosciences
• ACOBIOM
• Enrolmmun
• ADx NeuroSciences NV
• Qiagen
• PERKINELMER INC.
• F. Hoffman La-Roche Ltd.
• Shimadzu Corporation
• Neurobio
• Myriad RBM (Myriad Genetics, Inc.)

Recent Developments

• In November 2024, dannce.AI raises $2.6 million; launches to provide clinicians and drug developers an ai biomarkers platform to characterize drug effects and optimize neurological care DANNCE is a new approach to the clinical exam that ingests videos of patients and automatically analyzes them for evidence of neurological disease. (Source: https://www.globenewswire.com)
• In September 2024, Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry and neurology, announced the launch of MindLight, the first circular RNA biomarker-based assay designed to predict whether a patient with depression, also known as major depressive disorder, will respond to selective serotonin reuptake inhibitor (SSRI) antidepressant treatment. (Source: https://www.prnewswire.com)
• In April 2024, in New York, new research to identify biomarkers for cerebral amyloid angiopathy (CAA) and related CAA-related inflammation by comparing measures of BBB (blood-brain barrier) disruption and inflammation between 2 groups of patients was launched by Presbyterian and Weill Cornell Medicine neurologist, Samuel Bruce, MD.
• In May 2024, to develop a new TBI (traumatic brain injury) diagnostics, with an added focus on diagnosing mild TBI, Danaher announced they launched a collaboration with Johns Hopkins University. It helps to potentially initiate a correlation between a new biomarker panel and clinical outcomes.

Segments Covered in the Report

By Type

• Genomic
• Proteomic
• Metabolomic
• Imaging
• Others

By Application

• Alzheimer’s Disease
• Parkinson’s Disease
• Multiple Sclerosis
• Autism Spectrum Disorder
• Others

By End-use

• Hospital & Hospital Laboratories
• Independent clinical diagnostic centers
• Research Organizations & Others

By Region

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa